[A20-32] Abemaciclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V

Last updated 15.06.2020

Project no.:
A20-32

Commission:
Commission awarded on 16.03.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication/Intervention:

Patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer

Result of dossier assessment:

Initial endocrine-based therapy in postmenopausal patients and therapy in pre- and perimenopausal patients who have received prior endocrine therapy: hint of lesser benefit; postmenopausal women who have received prior endocrine therapy: indication of minor added benefit.

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Current document

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.